Adverse outcomes in trials of graded exercise therapy for adult patients with chronic fatigue syndrome.
White, P D, Etherington, J · Journal of psychosomatic research · 2021 · DOI
Quick Summary
This study reviewed 10 previous trials involving 1,279 people to examine whether graded exercise therapy (GET) causes harm in ME/CFS patients. Researchers compared how many people reported feeling much worse, stopped treatment, or dropped out of follow-up appointments between those doing GET and those receiving other treatments. The study found no clear evidence that GET caused more people to report feeling worse than other treatments, though more GET participants did drop out of follow-up appointments.
Why It Matters
Safety concerns about GET are significant for ME/CFS patients considering this treatment. This comprehensive review directly addresses whether GET causes harm, providing evidence that informs patient decision-making and clinical practice. The findings help distinguish between actual adverse outcomes and dropout patterns, which may reflect different reasons for leaving studies.
Observed Findings
14/333 (4%) participants reported much worse or very much worse after GET compared to 26/334 (8%) in control groups
64/535 (12%) participants withdrew from GET treatment compared to 53/534 (10%) in control groups
74/679 (11%) participants dropped out of GET trial follow-up compared to 41/600 (7%) in control groups
All 10 published GET trials included 1,279 total participants across multiple research centers
Inferred Conclusions
No excess harm was evident from GET based on self-rated deterioration or treatment withdrawal rates compared to control interventions
Higher dropout rates from follow-up in GET groups may reflect factors other than harm, such as treatment demands or perceived lack of benefit
Future research should identify the most effective and safest protocols for GET delivery in ME/CFS populations
Remaining Questions
Why did participants drop out of follow-up more frequently in GET groups—was this due to adverse effects, treatment burden, or other factors?
Does GET affect different patient subgroups differently, and are certain baseline characteristics associated with higher risk of deterioration?
What specific GET protocols, intensities, and individualization approaches minimize dropouts while maintaining efficacy?
What This Study Does Not Prove
This study does not prove GET is universally safe or effective for all ME/CFS patients—evidence certainty was low and results show no difference from controls in harm measures, not necessarily that GET is beneficial. It does not identify who might be at higher risk of negative outcomes or why dropout rates increased. The findings reflect published trials only, which may not capture all adverse events from clinical practice.